PCSA — Processa Pharmaceuticals Share News
0.000.00%
Last trade - 00:00NASDAQ TRADE HALT HALT NEWS PENDING AT 07:50 PM
Brief: Processa Pharmaceuticals To Effect 1-For-25 Reverse Stock Split
Processa Pharmaceuticals Inc expected to post a loss of 12 cents a share - Earnings Preview
Brief: Processa Pharmaceuticals Secures Strategic Investment And Evaluates Corporate Crypto Treasury Strategies
Brief: Processa Pharmaceuticals Terminates Licensing Agreement With Ocuphire Pharma - SEC Filing
Brief: Processa Pharmaceuticals Provides Portfolio And Business Update
Processa Pharmaceuticals Inc expected to post a loss of 77 cents a share - Earnings Preview
Brief: Processa Pharmaceuticals Inc - On Feb 4, Received Nasdaq Notice For Bid Price Non-Compliance
Brief: Processa Pharmaceuticals Announces Pricing Of $5 Mln Public Offering Priced At-The-Market Under Nasdaq Rules
Brief: Processa Pharmaceuticals Provides Product Pipeline And Financial Update
Brief: Processa Pharmaceuticals Announces Positive Preclinical Data for NGC-Iri
Processa Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary
Processa Pharmaceuticals Inc expected to post a loss of $1.02 a share - Earnings Preview
Processa Pharmaceuticals Inc expected to post a loss of 98 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Affirm, Calavo Growers, Shoals Technologies
U.S. STOCKS ON THE MOVE-Spotify, Affirm, Calavo Growers
Processa rises on positive data from early-stage study on cancer treatment
Brief: Processa Pharmaceuticals Announces Positive Efficacy Results From Preliminary Evaluation Of Phase 1B Dose-Escalating Trial With NGC-Cap In Gastrointestinal Cancer
Brief: Processa Pharmaceuticals Inc - May Offer And Sell Shares Of Common Stock Of Up To $2.4 Million From Time To Time